Skip to content

USE OF YASHTIMADHU ASCHYOTAN IN THE MANGEMENT OF SIRAJAL (EPISCLERITIS)

A RANDOMISED CONTROLLED TRIAL ON YASHTIMADHU ASCHYOTAN IN SIRAJAL WITH SPECIAL REFERENCE TO EPISCLERITIS

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020226
Enrollment
70
Registered
2019-07-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H151- Episcleritis

Interventions

Intervention1: Yashtimadhu aschyotan eye drop: Yashtimadhu aschyotan eye drop will be inserted in infected eye 4 times daily for first 7 days and 3 times daily for next 7 days.assessment will be done

Sponsors

Self Vishal Bapu Ratnaparkhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient suffering from Episcleritis. 2.Patients who are ready to accept the treatment will be selected.

Exclusion criteria

Exclusion criteria: 1.Patients having local cause such as foreign body or granuloma. 2.Patients were suffering from Anemia,Gastrointestinal bleeding. 3.Patients taking anticoagulant medication. 4.Patients suffering from Acute stage of infectious eye disease,severe allergic diathesis. 5.Pregnant Women. 6.General and local wound healing,congential anomalies of eye.

Design outcomes

Primary

MeasureTime frame
1.To study the efficacy of Yashtimadhu Aschyotan in Sirajal with special reference to episcleritis. 2.To compare whether the Yashtimadhu Aschyotan is more effective in treatment of Episcleritis.Timepoint: 18 months

Secondary

MeasureTime frame
1.To study the Sirajal according to Ayurveda and Episcleritis in modern point of view. 2.To Established Ayurvedic line of Treatment with its modern management of Episcleritis.Timepoint: One and Half year

Countries

India

Contacts

Public ContactDr Vijay Dhakate

Government Ayurved College and hospital Nagpur

drvijaydhakate6@gmail.com9860517302

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026